Different immunogenicity but similar antitumor efficacy of two DNA vaccines coding for an antigen secreted in different membrane vesicle-associated forms

Journal of Extracellular Vesicles

Volumn 3, Issue 1, 2014, Pages

  Sedlik, Christine ^a,b   Vigneron, James ^a,c,d   Torrieri Dramard, Lea ^c,d   Pitoiset, Fabien ^c,d   Denizeau, Jordan ^b   Chesneau, Caroline ^a   de la Rochere, Philippe ^a   Lantz, Olivier ^a,b   Thery, Clotilde ^a,b   Bellier, Bertrand ^c,d,e  

^a PSL RESEARCH UNIVERSITY   (France)

^b INSTITUT CURIE   (France)

^c SORBONNE UNIVERSITÉ   (France)

^d Sorbonne Université   (France)

^e ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

Author keywords

Exosomes; Extracellular vesicles; Microvesicles; Tumour immunity; Vaccination; Virus like particles

Indexed keywords

C1C2 PROTEIN; CAPSID PROTEIN; CD4 ANTIGEN; CD8 ANTIGEN; DNA VACCINE; GAG PROTEIN; IMMUNOGLOBULIN CLASS; IMMUNOGLOBULIN G ANTIBODY; LACTADHERIN; LIPID; MEMBRANE ANTIGEN; OVALBUMIN; PLASMID DNA; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN EXPRESSION; ANTIGEN SPECIFICITY; ARTICLE; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; CROSS PRESENTATION; DRUG EFFICACY; DRUG MEGADOSE; EXOSOME; FEMALE; FIBROSARCOMA; IMMUNOGENICITY; IMMUNOSTIMULATION; IN VIVO STUDY; LOW DRUG DOSE; MELANOMA; MEMBRANE VESICLE; MOUSE; NONHUMAN; PROTEIN DOMAIN; PROTEIN MODIFICATION; RETROVIRIDAE; THYMOMA; TUMOR IMMUNITY; VIRUS LIKE AGENT;

EID: 84990021573     PISSN: None     EISSN: 20013078     Source Type: Journal    
DOI: 10.3402/jev.v3.24646     Document Type: Article

References (33)

1. Finn OJ. Cancer vaccines: between the idea and the reality. Nat Rev Immunol. 2003;3:630-41.
2. Rice J, Ottensmeier CH, Stevenson FK. DNA vaccines: precision tools for activating effective immunity against cancer. Nat Rev Cancer. 2008;8:108-20.
3. Liu MA. DNA vaccines: an historical perspective and view to the future. Immunol Rev. 2011;239:62-84.
4. Guermonprez P, Valladeau J, Zitvogel L, Thery C, Amigorena S. Antigen presentation and T cell stimulation by dendritic cells. Annu Rev Immunol. 2002;20:621-67.
5. Joffre OP, Segura E, Savina A, Amigorena S. Crosspresentation by dendritic cells. Nat Rev Immunol. 2012;12: 557-69.
6. Li M, Davey GM, Sutherland RM, Kurts C, Lew AM, Hirst C, et al. Cell-associated ovalbumin is cross-presented much more efficiently than soluble ovalbumin in vivo. J Immunol. 2001;166:6099-103.
7. Belizaire R, Unanue ER. Targeting proteins to distinct subcellular compartments reveals unique requirements for MHC class I and II presentation. Proc Natl Acad Sci U S A. 2009;106:17463-8.
8. Graham DB, Stephenson LM, Lam SK, Brim K, Lee HM, Bautista J, et al. An ITAM-signaling pathway controls crosspresentation of particulate but not soluble antigens in dendritic cells. J Exp Med. 2007;204:2889-97.
9. Wolfers J, Lozier A, Raposo G, Regnault A, Thery C, Masurier C, et al. Tumor-derived exosomes are a source of shared tumor rejection antigens for CTL cross-priming. Nat Med. 2001;7:297-303.
10. Qazi KR, Gehrmann U, Domange Jordo E, Karlsson MC, Gabrielsson S. Antigen-loaded exosomes alone induce Th1-type memory through a B-cell-dependent mechanism. Blood. 2009;113:2673-83.
11. Zeelenberg IS, Ostrowski M, Krumeich S, Bobrie A, Jancic C, Boissonnas A, et al. Targeting tumor antigens to secreted membrane vesicles in vivo induces efficient antitumor immune responses. Cancer Res. 2008;68:1228-35.
12. Thery C, Regnault A, Garin J, Wolfers J, Zitvogel L, Ricciardi-Castagnoli P, et al. Molecular characterization of dendritic cell-derived exosomes. Selective accumulation of the heat shock protein hsc73. J Cell Biol. 1999;147:599-610.
13. Hanayama R, Tanaka M, Miwa K, Shinohara A, Iwamatsu A, Nagata S. Identification of a factor that links apoptotic cells to phagocytes. Nature. 2002;417:182-7.
14. Veron P, Segura E, Sugano G, Amigorena S, Thery C. Accumulation of MFG-E8/lactadherin on exosomes from immature dendritic cells. Blood Cells Mol Dis. 2005;35:81-8.
15. Rountree RB, Mandl SJ, Nachtwey JM, Dalpozzo K, Do L, Lombardo JR, et al. Exosome targeting of tumor antigensexpressed by cancer vaccines can improve antigen immunogenicity and therapeutic efficacy. Cancer Res. 2011;71:5235-44.
16. Hartman ZC, Wei J, Glass OK, Guo H, Lei G, Yang XY, et al. Increasing vaccine potency through exosome antigen targeting. Vaccine. 2011;29:9361-7.
17. Bellier B, Klatzmann D. Virus-like particle-based vaccines against hepatitis C virus infection. Expert Rev Vaccines. 2013; 12:143-54.
18. Bellier B, Dalba C, Clerc B, Desjardins D, Drury R, Cosset FL, et al. DNA vaccines encoding retrovirus-based virus-like particles induce efficient immune responses without adjuvant. Vaccine. 2006;24:2643-55.
19. Huret C, Desjardins D, Miyalou M, Levacher B, Amadoudji Zin M, Bonduelle O, et al. Recombinant retrovirus-derived virus-like particle-based vaccines induce hepatitis C virusspecific cellular and neutralizing immune responses in mice. Vaccine. 2013;31:1540-7.
20. Bellier B, Huret C, Miyalou M, Desjardins D, Frenkiel MP, Despres P, et al. DNA vaccines expressing retrovirus-like particles are efficient immunogens to induce neutralizing antibodies. Vaccine. 2009;27:5772-80.
21. Lescaille G, Pitoiset F, Macedo R, Baillou C, Huret C, Klatzmann D, et al. Efficacy of DNA vaccines forming e7 recombinant retroviral virus-like particles for the treatment of human papillomavirus-induced cancers. Hum Gene Ther. 2013;24:533-44.
22. Thery C, Amigorena S, Raposo G, Clayton A. Isolation and characterization of exosomes from cell culture supernatants and biological fluids. Curr Protoc Cell Biol. 2006;Chapter 3:Unit 3 22.
23. Thery C, Ostrowski M, Segura E. Membrane vesicles as conveyors of immune responses. Nat Rev Immunol. 2009;9: 581-93.
24. Chiarella P, Fazio VM, Signori E. Electroporation in DNA vaccination protocols against cancer. Curr Drug Metab. 2013; 14:291-9.
25. Zeelenberg IS, van Maren WW, Boissonnas A, Van Hout-Kuijer MA, Den Brok MH, Wagenaars JA, et al. Antigen localization controls T cell-mediated tumor immunity. J Immunol. 2011;187:1281-8.
26. Ahlén G, Söderholm J, Tjelle T, Kjeken R, Frelin L, Höglund U, et al. In vivo electroporation enhances the immunogenicity of hepatitis C virus nonstructural 3/4A DNA by increased local DNA uptake, protein expression, inflammation, and infiltration of CD3-T cells. J Immunol. 2007;179:4741-53.
27. Widera G, Austin M, Rabussay D, Goldbeck C, Barnett SW, Chen M, et al. Increased DNA vaccine delivery and immunogenicity by electroporation in vivo. J Immunol. 2000;164: 4635-40.
28. Daud AI, DeConti RC, Andrews S, Urbas P, Riker AI, Sondak VK, et al. Phase I trial of interleukin-12 plasmid electroporation in patients with metastatic melanoma. J Clin Oncol. 2008;26:5896-903.
29. Tjelle T, Rabussay D, Ottensmeier C, Mathiesen I, Kjeken R. Taking electroporation-based delivery of DNA vaccination into humans: a generic clinical protocol. Methods Mol. Biol. 2008;423:497-507.
30. Senovilla L, Vacchelli E, Garcia P, Eggermont A, Fridman WH, Galon J, et al. Trial watch: DNA vaccines for cancer therapy. Oncoimmunology. 2013;2:e23803.
31. Crescitelli R, Lasser C, Szabo TG, Kittel A, Eldh M, Dianzani I, et al. Distinct RNA profiles in subpopulations of extracellular vesicles: apoptotic bodies, microvesicles and exosomes. J Extracell Vesicles. 2013;2:20677. doi: 10.3402/jev.v2i0.20677.
32. Manolova V, Flace A, Bauer M, Schwarz K, Saudan P, Bachmann MF. Nanoparticles target distinct dendritic cell populations according to their size. Eur J Immunol. 2008;38: 1404-13.
33. Lattanzi L, Federico M. A strategy of antigen incorporation into exosomes: comparing cross-presentation levels of antigens delivered by engineered exosomes and by lentiviral virus-like particles. Vaccine. 2012;30:7229-37.